Therefore, a dual mechanistic basis for CADD522 action in BC may be operative: RUNX2-mediated glycolysis inhibition through suppression of Glut-1 gene expression [52] and RUNX2-independent mitochondrial dysfunction through repression of the activity of mitochondrial ATP synthase, an alternative target for CADD522. This evidence concerns the gene SLC2A1 and breast cancer.